Insmed Incorporated

INSM

Held by 6 specialist biotech funds

High Convergence

Share on X

Fund Holdings

6 fund convergence

Baker Bros. Advisors Driehaus Capital OrbiMed Advisors

Position Trend

Feb 13, 2026

$84.2M

1 fund

Feb 17, 2026

$2068.6M

5 funds

+2358% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 6,592,746Value: $1147.4M

**Signal Note: Baker Bros. Initiates ~$1.15B Position in Insmed (INSM)** Baker Bros.' new concentrated position in Insmed is a high-conviction bet almost certainly centered on brensocatib, a DPP1 inhibitor that delivered strong Phase 3 ASPEN results in bronchiectasis (reducing exacerbations ~21%) and is under FDA review with a PDUFA target date of August 2, 2025. The position size — over $1.1B — is extraordinary even for Baker Bros. and suggests confidence in both approval and commercial potential in a disease with no approved therapies in the US, representing a multi-billion-dollar market opportunity. Key near-term catalysts include the PDUFA decision and potential EU filing, with any Advisory Committee meeting (if scheduled) serving as an interim inflection point.

Driehaus CapitalNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

NBIX3 funds ALKS3 funds IRON3 funds PRAX3 funds EWTX3 funds ELVN3 funds SYRE3 funds PHVS

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Driehaus Initiates $18.4M Position in INSM Driehaus Capital's new $18.4M stake in Insmed signals conviction in the company's lead asset Arikayce (amikacin liposome inhalation suspension), an inhaled antibiotic approved for nontuberculous mycobacterial (NTM) lung infections with a validated orphan disease market. The timing likely reflects confidence in Arikayce's commercial ramp and potential label expansion catalysts, including the ongoing Phase 3 trial in CF-related mycobacterial infections and European regulatory progress. For a growth-focused manager, this entry suggests belief in INSM's ability to achieve meaningful revenue inflection from a large but underserved patient population.